GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (SHSE:688505) » Definitions » EPS without NRI

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) EPS without NRI : ¥0.10 (TTM As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co EPS without NRI?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's earnings per share without non-recurring items for the three months ended in Jun. 2024 was ¥0.09. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2024 was ¥0.10.

During the past 12 months, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's average earnings per share (NRI) Growth Rate was -56.50% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was -20.60% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -11.60% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was -1.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EPS without NRI or its related term are showing as below:

SHSE:688505' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -20.6   Med: 11.75   Max: 43.3
Current: -20.6

During the past 13 years, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 43.30% per year. The lowest was -20.60% per year. And the median was 11.75% per year.

SHSE:688505's 3-Year EPS without NRI Growth Rate is ranked worse than
82.86% of 817 companies
in the Drug Manufacturers industry
Industry Median: 8.6 vs SHSE:688505: -20.60

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EPS (Diluted) for the three months ended in Jun. 2024 was ¥0.07. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was ¥0.10.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EPS (Basic) for the three months ended in Jun. 2024 was ¥0.07. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 was ¥0.10.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co EPS without NRI Historical Data

The historical data trend for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co EPS without NRI Chart

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.13 0.17 0.11 0.07

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Quarterly Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.01 0.01 0.09 -

Competitive Comparison of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EPS without NRI

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's PE Ratio without NRI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's PE Ratio without NRI falls into.



Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co  (SHSE:688505) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co EPS without NRI Related Terms

Thank you for viewing the detailed overview of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Business Description

Traded in Other Exchanges
Address
308 Cailun Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai, CHN, 201210
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. Geographically, it derives revenue from Mainland China.
Executives
Zhang Wen Bo Core technical personnel
Jiang Jian Ping Core technical personnel
Tao Ji Ning Core technical personnel
Shen Yi Jun Core technical personnel
Li Jun senior management
Xue Yan senior management
Wang Luo Chun Supervisors, core technical personnel
Su Yong Directors, senior managers
Zhao Da Jun Directors, senior managers
Yang Xiao Lin senior management
Gan Yi Min Senior management, core technical personnel
Yu Dai Qing Supervisors

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Headlines

No Headlines